Nordson Raises Full-Year Guidance After Record Q3: Sales Up 10%, Adjusted EPS $3.25
NDSN sits 47% above its 52-week low of $213.23.
Summary
Nordson reported record Q3 FY2026 results with sales up 10% to $818M and adjusted EPS of $3.25, beating guidance. The company raised full-year sales and EPS guidance on a 35% backlog increase.
Key Events · Earnings and Guidance · NDSN
-
Record Q3 Sales and EPS
Sales reached an all-time quarterly record of $818 million, up 10% year-over-year. Adjusted EPS was $3.25, up 19% and above the high end of guidance.
-
Full-Year Guidance Raised
Company now expects FY2026 sales of $3,035–$3,075 million and adjusted EPS of $11.80–$12.00, up from prior guidance, driven by strong order entry and backlog.
-
Backlog Up 35%
Backlog increased 35% compared to the prior year, indicating sustained demand momentum entering Q4.
-
Segment Strength Broad-Based
All three segments posted record sales. Advanced Technology Solutions grew 28% with EBITDA up 58%; Medical and Fluid Solutions sales rose 5% with EBITDA up 6%.
Analysis · NDSN · Technology
Nordson delivered record Q3 results with sales of $818 million, up 10% year-over-year, and adjusted EPS of $3.25, beating the high end of guidance. The company raised full-year sales guidance to $3.035–$3.075 billion and adjusted EPS to $11.80–$12.00, driven by a 35% increase in backlog. All three segments posted record sales, with Advanced Technology Solutions leading at 28% growth. The stock trades near its 52-week high, and this earnings beat with raised guidance confirms strong momentum across diversified end markets.
At the time of this filing, NDSN was trading at $313.00 on NASDAQ in the Technology sector, with a market capitalization of approximately $17.3B. The 52-week trading range was $213.23 to $315.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.